Acompanhamento medicamentoso em pacientes pós-infecção por Covid-19: Medication follow-up in patients after Covid-19 infection

Vitor  Bezerra da Silva; Fabrício Kleber Kleber de Lucena Carvalho; Tiago Bezerra de Sá de Souza Nogueira

doi:10.47456/rbps.v24i4.39587

Autores

Vitor Bezerra da Silva UNIFIP https://orcid.org/0000-0002-4335-4971
Fabrício Kleber Kleber de Lucena Carvalho Unifip
Tiago Bezerra de Sá de Souza Nogueira Unifip

DOI:

https://doi.org/10.47456/rbps.v24i4.39587

Palavras-chave:

Covid-19, Tratamento, Cardiovascular

Resumo

Introdução: A Covid-19 é uma doença infecciosa causada pelo vírus SARS-Cov-2, o qual gera uma síndrome respiratória aguda grave e que levou a uma pandemia recente, iniciada no ano de 2020, com morbidade e mortalidade sem precedentes. Apesar de tudo o que se sabe sobre o tratamento do SARS-Cov-2 e sobre as vacinas produzidas, ainda há um elevado número de mortes por questões que não estão relacionadas à vacina, mas, sobretudo, no que diz respeito a eventos cardiovasculares. Objetivos: O objetivo desta pesquisa é avaliar se o tratamento medicamentoso utilizado é o correto e se surtem os efeitos positivos esperados, desmistificando as questões levantadas pela mídia sobre os efeitos colaterais das vacinas. Métodos: Trata-se de uma Revisão Sistemática, para a qual foram selecionados 15 artigos a partir das bases de dados U.S. National Library of Medicine and the National Institutes of Health (PubMed) e Biblioteca Virtual em Saúde (BVS). Resultados: As publicações levam à percepção de que os desfechos cardiovasculares observados em pacientes infectados pelo SARS-Cov-2 devem-se à própria fisiopatologia da doença e ao seu manejo inadequado, desviando a responsabilidade das vacinas para tais feitos. Conclusão: Conclui-se, portanto, que o tratamento eficaz deve ser instituído no intuito de evitar eventos tromboembólicos e isquêmicos, advindos da Covid-19, e que a vacinação deve ser incentivada por não trazer tais riscos.

Downloads

Não há dados estatísticos.

Referências

Arruda DE, Martins DD, Silva IF, Sousa MN. Prognóstico de pacientes com Covid-19 e doenças crônicas. Comun Ciênc Saúde [Internet]. 9 abr 2021 [citado 30 nov 2022];31(03):79-88.

Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, et al. Anticoagulation in patients with Covid-19. J Am College Cardiol [Internet]. mar 2022 [citado 30 nov 2022];79(9):917-28.

Our World in Data [Internet]. Covid-19 data explorer; [citado 24 mar 2022]. Disponível em: https:// ourworldindata.org/explorers/coronavirus-data-explorer

Bezerra LA, Rodrigues JE, Souto HL, Nóbrega RA, Silva NS, Sousa MN. Atuação de uma equipe multiprofissional em tempos de Coronavírus. Rev interdisc saúde [Internet]. 17 set 2020 [citado 30 nov 2022];7(único):1993-2008.

World Health Organization (WHO) [Internet]. Coronavirus disease (Covid-19): How is it transmitted? [citado 24 mar 2022]. Disponível em: https://www.who. int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted

Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of Covid-19. Science [Internet]. 11 mar 2022 [citado 30 nov 2022];375(6585):1122-7.

World Health Organization (WHO) [Internet]. Clinical management of Covid-19. 27 mai 2020. Disponível em: https://www.who.int/teams/health-care-readiness/covid-19

Lee AR, Wong SY, Chai LY, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of Covid-19 vaccines in immune-compromised patients: systematic review and meta-analysis. BMJ [Internet]. 2 mar 2022 [citado 30 nov 2022]:e068632.

Al‐Ali D, Elshafeey A, Mushannen M, Kawas H, Shafiq A, Mhaimeed N, et al. Cardiovascular and hematological events post Covid‐19 vaccination: a systematic review. J Cell Molec Med [Internet]. 29 dez 2021 [citado 30 nov 2022];26(3):636-53.

Sampaio R, Mancini M. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Rev Bras Fisiot [Internet]. Fev 2007 [citado 30 nov 2022];11(1):83-9.

Biblioteca Virtual em Saúde MS [Internet]. [citado 30 nov 2022]. Disponível em: https://bvsms.saude.gov.br/bvs/ ct/PDF/diretriz_do_grade.pdf

Falavigna M, Colpani V, Stein C, Azevedo LC, Bagattini AM, Brito GV, et al. Guidelines for the pharmacological treatment of Covid-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Brasil Terap Intens [Internet]. 2020 [citado 30 nov 2022];32(2).

Kosiborod MN, Esterline R, Furtado RH, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with Covid-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabet Endocrinol [Internet]. Set 2021 [citado 30 nov 2022];9(9):586-94.

Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with Covid-19 admitted to hospital: rapid randomised clinical trial. BMJ [Internet]. 14 out 2021 [citado 30 nov 2022]:n2400.

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy and safety of Covid-19 convalescent plasma in hospitalized patients. JAMA Inter Med [Internet]. 1 fev 2022 [citado 30 nov 2022];182(2):115.

Bikdeli B, Talasaz AH, Sharif-Kashani B, Rashidi F, Taghi Beigmohammad MI, et al. Atorvastatin versus placebo in patients with Covid-19 in intensive care: randomized controlled trial. BMJ. 7 jan 2022;407(68):376.

Rodrigues C, Freitas-Santos RS, Levi JE, Senerchia AA, Lopes AT, Santos SR, et al. Hydroxychloroquine plus azithromycin early treatment of mild Covid-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Internat J Antimicrob Agents [Internet]. Ago 2021 [citado 30 nov 2022]:106428.

Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernandez ML, Alvisi MF, et al. High-dose ivermectin for early treatment of Covid-19 (cover study): a randomised, double-blind, multicenter, phase II, dose-finding, proof-of-concept clinical trial. Internat J Antimicrob Agents [Internet]. Fev 2022 [citado 30 nov 2022];59(2):106516.

Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafi‐Rasi A, Raoufi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe Covid‐19. Immun Inflam Disease [Internet]. 11 nov 2021 [citado 30 nov 2022];10(2):201-8.

Granfeldt A, Andersen LW, Vallentin MF, Hilberg O, Hasselstrøm JB, Sørensen LK, et al. Senicapoc treatment in Covid‐19 patients with severe respiratory insufficiency: a randomized, open‐Label, phase II trial. Acta Anaesthes Scand [Internet]. 11 abr 2022 [citado 30 nov 2022].

Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, et al. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with Covid-19. Am Heart J [Internet]. Maio 2022 [citado 30 nov 2022];247:76-89.

Zdanyte M, Rath D. Cardiovascular risk assessment in Covid-19. Hämostaseo [Internet]. 11 ago 2021 [citado 30 nov 2022].

Kornowski R, Witberg G. Acute myocarditis caused by Covid-19 disease and following Covid-19 vaccination. Open Heart [Internet]. mar 2022 [citado 30 nov 2022];9(1):e001957.

Cryer MJ, Farhan S, Kaufmann CC, Jäger B, Garg A, Krishnan P, et al. Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized Covid-19 positive patients: a review. Clin Appl Thromb/Hemost [Internet]. Jan 2022 [citado 30 nov 2022];28:107602962210743.

Terentes-Printzios D, Gardikioti V, Solomou E, Emmanouil E, Gourgouli I, Xydis P, et al. The effect of an mRNA vaccine against Covid-19 on endothelial function and arterial stiffness. Hypertens Res [Internet]. 10 mar 2022 [citado 30 nov 2022];45(5):846-55.

Kantarcioglu B, Iqbal O, Walenga JM, Lewis B, Lewis J, Carter CA, et al. An update on the pathogenesis of Covid-19 and the reportedly rare thrombotic events following vaccination. Clin Appl Thromb/Hemost [Internet]. 1 jan 2021 [citado 30 nov 2022];27:107602962110214.

Cabezón Villalba G, Amat-Santos IJ, Dueñas C, Lopez OteromD, Catala P, Aparisi A, et al. Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in Covid-19. Cardiol J [Internet]. 25 maio 2021 [citado 30 nov 2022];28(3):360-8.

Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with Covid-19. JAMA Internal Med [Internet]. 1 dez 2021 [citado 30 nov 2022];181(12):1612.

Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically Ill patients with Covid-19. JAMA [Internet]. 5 abr 2022 [citado 30 nov 2022];327(13):1247.

Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VC, Spyropoulos AC, de Oliveira CC, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalization for Covid-19 (Michelle): an open-label, multicenter, randomised, controlled trial. Lancet [Internet]. Jan 2022 [citado 30 nov 2022];399(10319):50- 9.

Pereira-Godoy JM, Russeff GJ, Cunha CH, Sato DY, Silva DF, Godoy HJ, et al. Increased prevalence of deep vein thrombosis and mortality in patients with Covid-19 at a referral center in Brazil. Phlebology J Venous Dis [Internet]. 8 set 2021 [citado 30 nov 2022]:026835552110419.